Frazier, Vivo Add To Rempex's $67.5M In Fundraising

Law360, New York (November 9, 2011, 6:13 PM EST) -- Rempex Pharmaceuticals Inc. raised $67.5 million in funding from investors including venture capital firms Frazier Healthcare Ventures and Vivo Ventures to continue developing treatments for bacteria resistant to antibiotics, the company said Wednesday.

Rempex raised the money in a Series B financing that included new investors Frazier and Vivo, and previous funders SV Life Sciences, OrbiMed Advisors LLC and Adams Street Partners, the biopharmaceutical company said in a statement.

The investment round brings Rempex's total fundraising efforts to $76 million since it was formed from parts of a company...
To view the full article, register now.